BioSpace News Archive

Eiger BioPharmaceuticals, Inc. reported that the Compensation Committee of Eiger’s Board of Directors granted stock options to purchase an aggregate of 290,000 shares of Eiger’s common stock to two newly hired employees.

Sarepta Therapeutics, Inc. granted equity awards on April 29, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 44 individuals hired by Sarepta in April 2022.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, in collaboration with the University of Oxford, today announced final results from its Phase 2b study in patients with Dupuytren’s disease.

Today, Xcardia Innovation Ltd., a private medical device company developing innovative cardiac pacemaker and defibrillator technology, announced the first-in-human use of its new Xtractor device in patients undergoing lead extraction procedures.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021.

Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.

The Muscular Dystrophy Association celebrates yesterday’s approval by the US Food and Drug Administration (FDA) to ravulizumab (Ultomiris) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.

Procaps Group S.A., a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced its financial results for the fourth quarter and fiscal year ended December 31, 2021.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), will hold a webcast on Monday, May 2, 2022 at 5:00am PT/8:00am ET to review the topline results from the Saturn-2 Phase 3 trial for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis and provide a brief corporate update.